Advertisement

The Role of Magnesium in Pathophysiology and Migraine Treatment

  • Sanam Dolati
  • Reza Rikhtegar
  • Amir Mehdizadeh
  • Mehdi YousefiEmail author
Article
  • 66 Downloads

Abstract

Migraine is one of the most common recurrent types of headache and is the seventh cause of disability. This neurological disorder is characterized by having pain in head and other various symptoms such as nausea, emesis, photophobia, phonophobia, and sometimes visual sensory disorders. Magnesium (Mg) is a necessary ion for human body and has a crucial role in health and life maintenance. One of the main roles of Mg is to conserve neurons electric potential. Therefore, magnesium deficiency can cause neurological complications. Migraine is usually related to low amounts of Mg in serum and cerebrospinal fluid (CSF). Deficits in magnesium have significant role in the pathogenesis of migraine. Mg has been extensively used in migraine prophylaxis and treatment. This review summarizes the role of Mg in migraine pathogenesis and the potential utilizations of Mg in the prevention and treatment of migraine with the emphasis on transdermal magnesium delivery.

Keywords

Migraine Magnesium Headaches Pathogenesis Treatment 

Notes

Acknowledgments

We would also like to show our gratitude to the Aging Research Institute, Tabriz University of Medical Sciences for supporting this work.

Contribution

Sanam Dolati wrote the manuscript and edited the final version of the manuscript. Reza Rikhtegar designed and wrote manuscript. Amir Mehdizadeh drew the table and submitted the paper. Mehdi Yousefi supervised the study and correspondence during the paper submission.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interests.

References

  1. 1.
    Arnold M (2018) Headache classification committee of the International Headache Society (IHS) the international classification of headache disorders. Cephalalgia 38(1):1–211CrossRefGoogle Scholar
  2. 2.
    Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, Carter A, Casey DC, Charlson FJ, Chen AZ (2016) Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388(10053):1545–1602CrossRefGoogle Scholar
  3. 3.
    Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M (2001) Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 41(7):646–657PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Stovner LJ, Andree C (2010) Prevalence of headache in Europe: a review for the Eurolight project. J Headache Pain 11(4):289PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S (2017) Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev 97(2):553–622PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Dolati S, Marofi F, Babaloo Z, Aghebati-Maleki L, Roshangar L, Ahmadi M, Rikhtegar R, Yousefi M (2018) Dysregulated network of miRNAs involved in the pathogenesis of multiple sclerosis. Biomed Pharmacother 104:280–290PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    de Boer I, van den Maagdenberg AM, Terwindt GM (2019) Advance in genetics of migraine. Curr Opin Neurol 32(3):413–421PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Shuen AY, Wong BY, Wei C, Liu Z, Li M, Cole DE (2009) Genetic determinants of extracellular magnesium concentration: analysis of multiple candidate genes, and evidence for association with the estrogen receptor α (ESR1) locus. Clin Chim Acta 409(1-2):28–32PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Society HCCotIH (2013) The international classification of headache disorders, (beta version). Cephalalgia 33(9):629–808CrossRefGoogle Scholar
  10. 10.
    Ong JJY, De Felice M (2017) Migraine treatment: current acute medications and their potential mechanisms of action. Neurotherapeutics:1–17Google Scholar
  11. 11.
    Khairmode DV, Kapare PR, Jadhav KL, Khade RH, Keskar CH, Ghongade KD, Kamble R, Mali AS (2018) Migraine is not just a headache. Pharma Sci Monit 9(1)Google Scholar
  12. 12.
    Giffin N, Lipton R, Silberstein S, Tvedskov J, Olesen J, Goadsby P (2005) The migraine postdrome: an electronic diary study. Cephalalgia 25(10):958Google Scholar
  13. 13.
    Louter M, Wardenaar K, Veen G, van Oosterhout W, Zitman F, Ferrari M, Terwindt G (2014) Allodynia is associated with a higher prevalence of depression in migraine patients. Cephalalgia 34(14):1187–1192PubMedCrossRefGoogle Scholar
  14. 14.
    Cozzolino O, Marchese M, Trovato F, Pracucci E, Ratto GM, Buzzi MG, Sicca F, Santorelli FM (2018) Understanding spreading depression from headache to sudden unexpected death. Front Neurol 9:19PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Mauskop A, Varughese J (2012) Why all migraine patients should be treated with magnesium. J Neural Transm 119(5):575–579PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Agarwal R, Agarwal P (2014) Pathogenetic role of magnesium deficiency in ophthalmic diseases. Biometals 27(1):5–18CrossRefGoogle Scholar
  17. 17.
    Sparaco M, Feleppa M, Lipton R, Rapoport A, Bigal M (2006) Mitochondrial dysfunction and migraine: evidence and hypotheses. Cephalalgia 26(4):361–372PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Burstein R, Noseda R, Borsook D (2015) Migraine: multiple processes, complex pathophysiology. J Neurosci 35(17):6619–6629PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Liebman TN, Crystal SC (2016) What is the evidence that riboflavin can be used for migraine prophylaxis? Einstein J Biol Med 27(1):7–9CrossRefGoogle Scholar
  20. 20.
    Cevoli S, Favoni V, Cortelli P (2019) Energy metabolism impairment in migraine. Curr Med ChemGoogle Scholar
  21. 21.
    Chhater S, Karal R, Kumar B (2018) Review on migraine: pathophysiology and treatment. Am J Biomed Res 6(1):20–24CrossRefGoogle Scholar
  22. 22.
    Malhotra R (2016) Understanding migraine: potential role of neurogenic inflammation. Ann Indian Acad Neurol 19(2):175–182PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Ho TW, Edvinsson L, Goadsby PJ (2010) CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 6(10):573–582PubMedCrossRefGoogle Scholar
  24. 24.
    Hoffmann J, Charles A (2018) Glutamate and its receptors as therapeutic targets for migraine. Neurotherapeutics 15(2):361–370PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Aggarwal M, Puri V, Puri S (2012) Serotonin and CGRP in migraine. Ann Neurosci 19(2):88–94PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Kojić Z, Stojanović D (2013) Pathophysiology of migraine: from molecular to personalized medicine. Med Pregl 66(1-2):53–57PubMedCrossRefGoogle Scholar
  27. 27.
    Hoffmann J (2011) Recent advances in headache research. Expert Rev Neurother 11(10):1379–1381PubMedCrossRefGoogle Scholar
  28. 28.
    Coppola G, Schoenen J (2012) Cortical excitability in chronic migraine. Curr Pain Headache Rep 16(1):93–100PubMedCrossRefGoogle Scholar
  29. 29.
    Karsan N, Goadsby PJ (2018) Biological insights from the premonitory symptoms of migraine. Nat Rev Neurol:1Google Scholar
  30. 30.
    Charbit AR, Akerman S, Goadsby PJ (2011) Trigeminocervical complex responses after lesioning dopaminergic A11 nucleus are modified by dopamine and serotonin mechanisms. PAIN® 152(10):2365–2376CrossRefGoogle Scholar
  31. 31.
    Chen Z, Chen X, Liu M, Dong Z, Ma L, Yu S (2017) Altered functional connectivity of amygdala underlying the neuromechanism of migraine pathogenesis. J Headache Pain 18(1):7PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Ong JJY, De Felice M (2018) Migraine treatment: current acute medications and their potential mechanisms of action. Neurotherapeutics 15(2):274–290PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Taylor FR (2011) Nutraceuticals and headache: the biological basis. Headache 51(3):484–501PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    De Baaij JH, Hoenderop JG, Bindels RJ (2015) Magnesium in man: implications for health and disease. Physiol Rev 95(1):1–46PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Romani AM (2013) Magnesium in health and disease. Interrelations between essential metal ions and human diseases. Springer, In, pp 49–79Google Scholar
  36. 36.
    Teigen L, Boes CJ (2015) An evidence-based review of oral magnesium supplementation in the preventive treatment of migraine. Cephalalgia 35(10):912–922PubMedCrossRefGoogle Scholar
  37. 37.
    Sun-Edelstein C, Mauskop A (2009) Role of magnesium in the pathogenesis and treatment of migraine. Expert Rev Neurother 9(3):369–379PubMedCrossRefGoogle Scholar
  38. 38.
    Pizza V, Milano W, Padricelli U, Capasso A (2017) NOVEL THERAPEUTIC INVESTIGATIONS IN MIGRAINE PAINGoogle Scholar
  39. 39.
    Nattagh-Eshtivani E, Sani MA, Dahri M, Ghalichi F, Ghavami A, Arjang P, Tarighat-Esfanjani A (2018) The role of nutrients in the pathogenesis and treatment of migraine headaches. Biomed Pharmacother 102:317–325PubMedCrossRefGoogle Scholar
  40. 40.
    Kirkland AE, Sarlo GL, Holton KF (2018) The Role of Magnesium in Neurological Disorders. Nutrients 10(6)PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Bianchi A, Salomone S, Caraci F, Pizza V, Bernardini R, D’Amato CC (2004) Role of magnesium, coenzyme Q10, riboflavin, and vitamin B12 in migraine prophylaxis.Google Scholar
  42. 42.
    Hoffmann J, Charles A (2018) Glutamate and its receptors as therapeutic targets for migraine. Neurotherapeutics:1–10Google Scholar
  43. 43.
    Shindo Y, Fujimoto A, Hotta K, Suzuki K, Oka K (2010) Glutamate-induced calcium increase mediates magnesium release from mitochondria in rat hippocampal neurons. J Neurosci Res 88(14):3125–3132PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Rybicka M, Baranowska-Bosiacka I, Zyluk B, Nowacki P, Chlubek D (2012) The role of magnesium in migraine pathogenesis. Potential use of magnesium compounds in prevention and treatment of migraine headaches. J Elementol 17(2)Google Scholar
  45. 45.
    Stuart S, Griffiths LR (2012) A possible role for mitochondrial dysfunction in migraine. Mol Gen Genomics 287(11-12):837–844CrossRefGoogle Scholar
  46. 46.
    Daniel O, Mauskop A (2016) Nutraceuticals in acute and prophylactic treatment of migraine. Curr Treat Options Neurol 18(4):14PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Izzati-Zade K (2008) The role of serotonin in the pathogenesis and clinical presentations of migraine attacks. Neurosci Behav Physiol 38(5):501–505PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Dussor G (2014) Serotonin, 5HT1 agonists, and migraine: new data, but old questions still not answered. Curr Opin Support Palliat Care 8(2):137PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Holland S, Silberstein S, Freitag F, Dodick D, Argoff C, Ashman E (2012) Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults:[RETIRED]: report of the quality standards subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 78(17):1346–1353PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Dolati S, Ahmadi M, Rikhtegar R, Babaloo Z, Ayromlou H, Aghebati-Maleki L, Nouri M, Yousefi M (2018) Changes in Th17 cells function after nanocurcumin use to treat multiple sclerosis. Int Immunopharmacol 61:74–81PubMedCrossRefGoogle Scholar
  51. 51.
    Nowak L, Bregestovski P, Ascher P, Herbet A, Prochiantz A (1984) Magnesium gates glutamate-activated channels in mouse central neurones. Nature 307(5950):462PubMedCrossRefGoogle Scholar
  52. 52.
    Seçil Y, Ünde C, Beckmann YY, Bozkaya YT, Özerkan F, Başoğlu M (2010) Blood pressure changes in migraine patients before, during and after migraine attacks. Pain Pract 10(3):222–227PubMedCrossRefGoogle Scholar
  53. 53.
    Olesen J (2008) The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache. Pharmacol Ther 120(2):157–171PubMedCrossRefGoogle Scholar
  54. 54.
    Yorns WR Jr, Hardison HH (2013) Mitochondrial dysfunction in migraine. Semin Pediatr Neurol 3. Elsevier:188–193CrossRefGoogle Scholar
  55. 55.
    Ong JJY, Wei DY-T, Goadsby PJ (2018) Recent advances in pharmacotherapy for migraine prevention: from pathophysiology to new drugs. Drugs 78(4):411–437PubMedCrossRefGoogle Scholar
  56. 56.
    Von Luckner A, Riederer F (2018) Magnesium in migraine prophylaxis—is there an evidence-based rationale? A systematic review. Headache 58(2):199–209CrossRefGoogle Scholar
  57. 57.
    DeMaagd G (2008) The pharmacological management of migraine, part 2: preventative therapy. Pharm Ther 33(8):480Google Scholar
  58. 58.
    Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB (2007) Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention Study: CME. Headache 47(3):355–363PubMedGoogle Scholar
  59. 59.
    Armstrong C (2013) AAN/AHS update recommendations for migraine prevention in adults. Am Fam Physician 87(8):584–585PubMedGoogle Scholar
  60. 60.
    Chruścikowska AJJOPH, NURSING, RESCUE M (2015) Migraine prophylaxis in pregnancy–the effects of magnesium. 142 (2015_2):07-10Google Scholar
  61. 61.
    Lodi R, Iotti S, Cortelli P, Pierangeli G, Cevoli S, Clementi V, Soriani S, Montagna P, Barbiroli B (2001) Deficient energy metabolism is associated with low free magnesium in the brains of patients with migraine and cluster headache. Brain Res Bull 54(4):437–441PubMedCrossRefGoogle Scholar
  62. 62.
    Pringsheim T, Davenport WJ, Becker WJ (2010) Prophylaxis of migraine headache. Can Med Assoc J 182(7):E269–E276CrossRefGoogle Scholar
  63. 63.
    Wang F, Van Den Eeden SK, Ackerson LM, Salk SE, Reince RH, Elin RJ (2003) Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Headache 43(6):601–610PubMedCrossRefGoogle Scholar
  64. 64.
    Kelley NE, Tepper DE (2012) Rescue therapy for acute migraine, part 1: triptans, dihydroergotamine, and magnesium. Headache 52(1):114–128PubMedCrossRefGoogle Scholar
  65. 65.
    Facchinetti F, Sances G, Borella P, Genazzani AR, Nappi G (1991) Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache 31(5):298–301PubMedCrossRefGoogle Scholar
  66. 66.
    Peikert A, Wilimzig C, Köhne-Volland R (1996) Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 16(4):257–263PubMedCrossRefGoogle Scholar
  67. 67.
    Esfanjani AT, Mahdavi R, Mameghani ME, Talebi M, Nikniaz Z, Safaiyan A (2012) The effects of magnesium, l-carnitine, and concurrent magnesium–l-carnitine supplementation in migraine prophylaxis. Biol Trace Elem Res 150(1-3):42–48CrossRefGoogle Scholar
  68. 68.
    Gaul C, Diener H-C, Danesch U, Group MS (2015) Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. J Headache Pain 16(1):32PubMedCentralCrossRefPubMedGoogle Scholar
  69. 69.
    Giorgio Dalla V, Zavarize P, Ngonga G, Pezzini A, Dalla Volta G (2017) Combination of tanacethum partenium, 5-hydrossitriptophan (5-Http) and magnesium in the prophylaxis of episodic migraine without aura (AURASTOP®) an observational study. Int J Neurol Brain Disord 4(1):0-0Google Scholar
  70. 70.
    Giorgio Dalla V, Antonaci F, Rebecchi V, Sances G, Merlo P, Giorgetti A, Di Palma F, Matta E, Dallocchio C, Tassorelli C (2018) AURASTOP ® in the treatment of migraine aura. Int J Neurol Brain Disord 5(1):11–14Google Scholar
  71. 71.
    Mainardi F, Merlo P, Maggioni F, Zanchin G, Dalla Volta G (2018) Efficacy of a combination of tanacetum parthenium, 5-hydroxy tryptophan and magnesium (Aurastop) in episodic migraine prevention: a multicentric observational study. Open Access Library J 5(08):1Google Scholar
  72. 72.
    Guilbot A, Bangratz M, Abdellah SA, Lucas C (2017) A combination of coenzyme Q10, feverfew and magnesium for migraine prophylaxis: a prospective observational study. BMC Complement Altern Med 17(1):433PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Karimi N, Razian A, Heidari M (2019) The efficacy of magnesium oxide and sodium valproate in prevention of migraine headache: a randomized, controlled, double-blind, crossover study. Acta Neurol Belg:1–7Google Scholar
  74. 74.
    Mauskop A, Altura BT, Cracco RQ, Altura BM (1996) Intravenous magnesium sulfate rapidly alleviates headaches of various types. Headache 36(3):154–160PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Demirkaya Ş, Vural O, Dora B, Topçuoğlu MA (2001) Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks. Headache 41(2):171–177PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Corbo J, Esses D, Bijur PE, Iannaccone R, Gallagher EJ (2001) Randomized clinical trial of intravenous magnesium sulfate as an adjunctive medication for emergency department treatment of migraine headache. Ann Emerg Med 38(6):621–627PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Bigal M, Bordini C, Tepper S, Speciali J (2002) Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study. Cephalalgia 22(5):345–353PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Frank LR, Olson CM, Shuler KB, Gharib SF (2004) Intravenous magnesium for acute benign headache in the emergency department: a randomized double-blind placebo-controlled trial. Can J Emerg Med 6(5):327–332Google Scholar
  79. 79.
    Cete Y, Dora B, Ertan C, Ozdemir C, Oktay C (2005) A randomized prospective placebo-controlled study of intravenous magnesium sulphate vs. metoclopramide in the management of acute migraine attacks in the Emergency Department. Cephalalgia 25(3):199–204PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Choi H, Parmar N (2014) The use of intravenous magnesium sulphate for acute migraine: meta-analysis of randomized controlled trials. Eur J Emerg Med 21(1):2–9PubMedPubMedCentralGoogle Scholar
  81. 81.
    Kasmaei HD, Amiri M, Negida A, Hajimollarabi S, Mahdavi N (2017) Ketorolac versus magnesium sulfate in migraine headache pain management; a preliminary study. Emergency 5(1)Google Scholar
  82. 82.
    Baratloo A, Mirbaha S, Delavar Kasmaei H, Payandemehr P, Elmaraezy A, Negida A (2017) Intravenous caffeine citrate vs. magnesium sulfate for reducing pain in patients with acute migraine headache; a prospective quasi-experimental study. Korean J Pain 30(3):176–182PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Ha H, Gonzalez A (2019) Migraine headache prophylaxis. Am Fam Physician 99(1)Google Scholar
  84. 84.
    Sprenger T, Viana M, Tassorelli C (2018) Current prophylactic medications for migraine and their potential mechanisms of action. Neurotherapeutics:1–11Google Scholar
  85. 85.
    Chiu H-Y, Yeh TH, Huang YC, Chen PY (2016) Effects of intravenous and oral magnesium on reducing migraine: a meta-analysis of randomized controlled trials. Pain Phys 19(1):E97–E112Google Scholar
  86. 86.
    Pagliaro MJ, Pagliaro MM (2014) Method and device or pharmaceutical compositions for the transdermal delivery of magnesium directly to the neuromuscular junction for the treatment of muscle cramping. Google PatentsGoogle Scholar
  87. 87.
    Gröber U, Werner T, Vormann J, Kisters K (2017) Myth or reality—transdermal magnesium? Nutrients 9(8):813PubMedCentralCrossRefGoogle Scholar
  88. 88.
    Shealy N (2000) Holy Water, Sacred oil: the fountain of youth. Biogenics Books, New YorkGoogle Scholar
  89. 89.
    Sircus M (2011) Transdermal magnesium therapy: a new modality for the maintenance of health. iUniverse,Google Scholar
  90. 90.
    Jepps OG, Dancik Y, Anissimov YG, Roberts MS (2013) Modeling the human skin barrier—Towards a better understanding of dermal absorption. Adv Drug Deliv Rev 65(2):152–168PubMedCrossRefGoogle Scholar
  91. 91.
    Bourke B (2008) Magnesium chloride for health and rejuvenation.Google Scholar
  92. 92.
    Reddy B Achieving optimal health through transdermal magnesium therapyGoogle Scholar
  93. 93.
    Chandrasekaran NC, Sanchez WY, Mohammed YH, Grice JE, Roberts MS, Barnard RT (2016) Permeation of topically applied Magnesium ions through human skin is facilitated by hair follicles. Magnes Res 29(2):35–42PubMedGoogle Scholar
  94. 94.
    Watkins K, Josling P (2010) A pilot study to determine the impact of transdermal magnesium treatment on serum levels and whole body CaMg ratios. Nutr Pract 14:1–7Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Sanam Dolati
    • 1
    • 2
    • 3
  • Reza Rikhtegar
    • 1
  • Amir Mehdizadeh
    • 4
  • Mehdi Yousefi
    • 2
    • 4
    • 5
    Email author
  1. 1.Aging Research InstituteTabriz University of Medical SciencesTabrizIran
  2. 2.Stem Cell Research CenterTabriz University of Medical SciencesTabrizIran
  3. 3.Student’s Research CommitteeTabriz University of Medical SciencesTabrizIran
  4. 4.Liver and Gastrointestinal Diseases Research CenterTabriz University of Medical SciencesTabrizIran
  5. 5.Department of Immunology, Faculty of MedicineTabriz University of Medical SciencesTabrizIran

Personalised recommendations